Lantheus Holdings, INC 10-Q quarterly reports

Lantheus Holdings reports Q2 2026 revenue growth driven by key products, while navigating a pending acquisition and regulatory updates.

Lantheus Holdings reported a 1.2% increase in revenue for the first quarter of 2026, driven by strong performance in Neuraceq and DEFINITY, despite a decrease in PYLARIFY sales.

Lantheus Holdings, Inc. reported a significant drop in Q3 net income and diluted EPS, driven by increased operating expenses and strategic investments, despite slight revenue growth.

Lantheus Holdings reports mixed Q2 2025 results with revenue declines in key products offset by strategic acquisitions and pipeline advancements.

Lantheus Holdings' Q1 2025 results show slight revenue growth, strategic moves in radiopharmaceuticals, and a focus on oncology and neurology.

Lantheus Holdings saw a significant increase in revenue and strategic expansion through acquisitions in the third quarter of 2024, primarily driven by PYLARIFY and DEFINITY sales.

Lantheus Holdings saw a significant increase in revenue and net income in the second quarter of 2024, fueled by strong sales of PYLARIFY and strategic acquisitions.

Lantheus Holdings experienced a significant increase in revenue and profitability in the first quarter of 2024, primarily driven by strong sales of PYLARIFY and DEFINITY.